Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference
Leap Therapeutics, Inc. (Nasdaq: LPTX) will present at B. Riley Securities' 3rd Annual Oncology Conference on January 18, 2022, at 1:30 p.m. Eastern Time. The presentation will be made by Douglas E. Onsi, President and CEO, Cynthia Sirard, MD, Chief Medical Officer, and Jason Baum, PhD, VP of Translational Medicine. Attendees can access the live webcast on the company's Investors page, with a replay available afterwards. Leap Therapeutics focuses on targeted and immuno-oncology therapies, with its leading candidate, DKN-01, in trials for various cancers.
- None.
- None.
CAMBRIDGE, Mass., Jan. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, Cynthia Sirard, MD, Chief Medical Officer, and Jason Baum, PhD., Vice President and Head of Translational Medicine will present a corporate overview at B. Riley Securities' 3rd Annual Oncology Conference. The conference will be held in a virtual meeting format.
B. Riley Securities' 3rd Annual Oncology Conference
Date: Wednesday, January 18, 2022
Time: 1:30 p.m. Eastern Time
The presentation will be webcast live and may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, where a replay of the event will also be available for a limited time.
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, colorectal, and gynecologic cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include Leap's expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in clinical studies, potential for the receipt of future option exercise, milestone, or royalty payments from BeiGene, financial runway, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19, global conflict or supply chain related issues; unstable global market and economic conditions; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially is included in Leap Therapeutics' periodic filings with the SEC, including Leap's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 11, 2022 and as may be updated by Leap's Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statement contained in this release speaks only as of its date. Leap undertakes no obligation to update any forward-looking statement contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
matthew@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-b-riley-securities-3rd-annual-oncology-conference-301718947.html
SOURCE Leap Therapeutics, Inc.
FAQ
When is Leap Therapeutics presenting at the B. Riley Securities Oncology Conference?
Who will represent Leap Therapeutics at the B. Riley Securities conference?
How can I access the Leap Therapeutics presentation?
What is the focus of Leap Therapeutics?
What is Leap Therapeutics' lead clinical candidate?
